Jaguar Animal Health (NASDAQ:JAGX) Posts Quarterly Earnings Results, Beats Estimates By $135.50 EPS

Posted by Geri Gentry on May 21st, 2026

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($149.10) by $135.50, FiscalAI reports. Jaguar Animal Health had a negative net margin of 464.20% and a negative return on equity of 1,194.94%. The company had revenue of $20.27 million for the quarter, compared to the consensus estimate of $4.21 million.

Jaguar Animal Health Price Performance

Shares of Jaguar Animal Health stock opened at $3.67 on Thursday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.29 and a current ratio of 0.50. The firm’s 50-day simple moving average is $11.42 and its 200-day simple moving average is $27.76. Jaguar Animal Health has a twelve month low of $2.53 and a twelve month high of $186.55. The firm has a market cap of $1.36 million, a P/E ratio of 0.00 and a beta of 0.01.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JAGX. Wall Street Zen upgraded shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a report on Sunday, May 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Stock Report on JAGX

About Jaguar Animal Health

(Get Free Report)

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.